We are live on
!
Find out more
BGI
B Group Inc Portfolio holdings
AUM
$135M
1-Year Est. Return
80%
This Fund
S&P 500
This Quarter
Est. Return
+4.02%
1 Year Est. Return
+80%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$136M
AUM Growth
+$6.01M
(+4.6%)
Cap. Flow
+$348K
Cap. Flow
% of AUM
0.26%
Top 10 Holdings %
Top 10 Hldgs %
87.81%
Holding
21
New
4
Increased
5
Reduced
3
Closed
1
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ADMA Biologics
ADMA
|
+$1.63M |
| 2 |
Ultragenyx Pharmaceutical
RARE
|
+$750K |
| 3 |
Spyre Therapeutics
SYRE
|
+$326K |
| 4 |
NRXPW
NRX Pharmaceuticals Warrant
NRXPW
|
+$255K |
| 5 |
GameSquare
GAME
|
+$247K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Insmed
INSM
|
+$19M |
| 2 |
Assembly Biosciences
ASMB
|
+$299K |
| 3 |
Praxis Precision Medicines
PRAX
|
+$170K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 73.52% |
| 2 | Communication Services | 0.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
ADMA Biologics
ADMA
$2.02B
| $35.4M | 26.02% |
2,412,542
+95,000
| +4% | +$1.63M |
|
2
PUT
Eli Lilly
LLY
$1.05T
| $17.2M | 12.63% |
22,500
+7,500
| +50% | +$5.58M |
|
3
PUT
NVIDIA
NVDA
$4.91T
| $14M | 10.29% |
+75,000
| New | +$13.1M |
|
4
Zai Lab
ZLAB
$2.28B
| $13.6M | 9.97% |
400,000
| – | – |
|
|
AKRO
5
DELISTED
Akero Therapeutics
AKRO
| $11M | 8.12% |
232,446
| – | – |
|
|
CLLS
6
Cellectis
CLLS
$265M
| $9.35M | 6.88% |
3,281,501
+25,000
| +0.8% | +$64.8K |
|
7
Taysha Gene Therapies
TSHA
$1.71B
| $5.89M | 4.33% |
1,800,556
| – | – |
|
|
8
Assembly Biosciences
ASMB
$531M
| $4.5M | 3.31% |
175,706
-13,644
| -7% | -$299K |
|
|
NRXPW
9
DELISTED
NRX Pharmaceuticals Warrant
NRXPW
| $4.46M | 3.28% |
+3,000,000
| New | +$255K |
|
|
10
Ultragenyx Pharmaceutical
RARE
$2.88B
| $4.06M | 2.99% |
135,000
+25,000
| +23% | +$750K |
|
11
Aura Biosciences
AURA
$723M
| $3.54M | 2.6% |
572,576
| – | – |
|
12
Iovance Biotherapeutics
IOVA
$2.23B
| $3.25M | 2.39% |
1,500,000
| – | – |
|
13
Sight Sciences
SGHT
$274M
| $3.2M | 2.35% |
930,000
| – | – |
|
|
14
Spyre Therapeutics
SYRE
$8.7B
| $1.68M | 1.23% |
100,000
+20,000
| +25% | +$326K |
|
|
15
Praxis Precision Medicines
PRAX
$8.77B
| $1.67M | 1.23% |
31,500
-3,500
| -10% | -$170K |
|
|
ORKA
16
Oruka Therapeutics
ORKA
$5.59B
| $1.44M | 1.06% |
75,000
| – | – |
|
17
Apogee Therapeutics
APGE
$10.1B
| $1.39M | 1.02% |
35,000
| – | – |
|
18
CALL
Replimune Group
REPL
$859M
| $210K | 0.15% |
+50,000
| New | +$320K |
|
|
19
GameSquare
GAME
$35.8M
| $170K | 0.12% |
+250,000
| New | +$247K |
|
|
20
Insmed
INSM
$23.5B
| $22.8K | 0.02% |
158
-154,842
| -100% | -$19M |
|
|
21
CALL
Ultragenyx Pharmaceutical
RARE
$2.88B
| – | – |
-67,600
| Closed | -$2.46M |
|
Similar funds
UOP
ICM
EC
AV
FA
GEH
SA
SCM
B Group Inc's Q3 2025 Portfolio in Review
As of Q3 2025, B Group Inc held 21 positions worth $136M, up 4.6% from $130M the previous quarter. Its ten largest holdings account for 88% of the portfolio.
B Group Inc's Q3 2025 filing shows 4 new, 5 increased, 3 reduced and 1 closed positions. Its largest new stake was NRX Pharmaceuticals Warrant: 3,000,000 shares worth $4.46M. The largest sale was Insmed, an estimated $19M.
By sector, the portfolio is most concentrated in Healthcare at 74% of assets, down from 89% a quarter earlier, followed by Communication Services.
- B Group Inc's largest Q3 2025 buy was NRX Pharmaceuticals Warrant: 3,000,000 shares worth $4.46M.
- B Group Inc added most to ADMA Biologics in Q3 2025, an estimated $1.63M increase.
- B Group Inc's biggest Q3 2025 reduction was Insmed, cutting an estimated $19M.
- B Group Inc's ten largest holdings make up 88% of its $136M portfolio in Q3 2025.
- B Group Inc opened 4 new positions and closed 1 in Q3 2025.
- B Group Inc's portfolio value rose 4.6% quarter-over-quarter to $136M.
Based on B Group Inc's 13F filing for Q3 2025, filed 14 Nov 2025.